Bausch Health Companies Inc. (BHC) 2002 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Unidentified

    Unidentified

  • (Webcast Begins in Progress)

    (網路直播已開始進行中)

  • ... $94 million. At this point I would like to hand it over to to continue the review. ? Hello. , did you want to continue on?

    … 9,400 萬美元。此時我想把時間交給,請他/她繼續進行回顧。? 你好。,你想要繼續嗎?

  • - President

    - President

  • Yes, I certainly will.

    是的,我當然會。

  • I think we had a telephone problem there, and I apologize. As everyone knows, is an two-receptor blocker or known as the class of drugs and it's for the treatment of hypertension and indicated for use either alone or in conjunction with other anti-hypertensives. is on patent until the year 2011 and this allows Biovail to enter one of the fastest growing segments of the antihypertensive market.

    我想剛才電話出了點問題,對此我致歉。眾所周知,是一種受體阻斷劑,或稱為類藥物,用於治療高血壓,適應症為可單獨使用或與其他降壓藥併用。的專利有效期至 2011 年,這使 Biovail 得以進入降壓藥市場中成長最快的細分領域之一。

  • The market in 2001 was characterized by growth in excess of 35 percent. As part of this arrangement, Biovail also acquired the rights to HCT which includes a dieretic and that was approved by the FDA in November 2001. Biovail plans on launching this combination product later this year. Combination products like HCT offers physicians additional dosing flexibility for the treatment of their patients. The combination class of and a diuretic were characterized by growth in excess of 50 percent per year in 2001.

    [] 市場在 2001 年的特徵是成長率超過 35%。作為此項安排的一部分,Biovail 也取得HCT 的權利,其中包含一種利尿劑,並已於 2001 年 11 月獲 FDA 核准。Biovail 計畫於今年稍晚推出此複方產品。像HCT 這類複方產品可為醫師在治療病患時提供更多劑量調整彈性。2001 年與利尿劑的複方類別年成長率超過 50%。

  • During the quarter, we also concluded a $400 million seven and seven-eighths senior subordinated note offering providing the company with an opportunity to pay off all of its previously outstanding cash interest bearing debts and to provide the company with capital for future products or technology acquisitions and for general corporate purposes.

    本季期間,我們也完成一項 4 億美元、票面利率 7 又 7/8% 的優先次順位票據發行,使公司得以償還先前所有仍在流通、需支付現金利息的債務,並為未來產品或技術併購及一般公司用途提供資金。

  • Biovail has also announced the acquisition of a 15 percent ownership position for approximately $65 million in SA, a European based company with leading drug delivery systems. has gained market authorizations for novel medications utilizing their delivery technologies in over 70 countries. Under the terms of the agreement, will develop six novel pharmaceutical products for commercialization by Biovail in North America and Mexico.

    Biovail 亦宣布以約 6,500 萬美元收購SA 15% 的持股;SA 為一家歐洲公司,擁有領先的藥物傳輸系統。已在 70 多個國家取得使用其傳輸技術之創新藥物的上市許可。依協議條款,

  • These products target Biovail therapeutic areas of focus and unleash market opportunities. will at their expense accelerate the development of these six products through phase three clinicals with the intention of receiving FDA approval and commercialization of the products in the 2005 to 2007 timeframe.

    這些產品鎖定 Biovail 的重點治療領域,並釋放市場機會。將自費加速這六項產品的開發,推進至第三期臨床試驗,目標是在 2005 至 2007 年間取得 FDA 核准並完成產品商業化。

  • Biovail and have agreed to cross license certain technologies and Biovail is licensing its C form technology and is licensing its flash tab technologies. The companies believe that by combining the two technologies a superior rapidly disintegrating dosage format with a strong patent protection can be further established.

    Biovail 與已同意就特定技術進行交叉授權;Biovail 授權其 C form 技術,而授權其 flash tab 技術。兩家公司相信,結合兩項技術可進一步建立具強大專利保護的優異快速崩解劑型。

  • And now I'd like to turn the call over to the more operational side and to talk to you about our activities in the United States. We have fully prepared and trained our sales representatives on Zovirax ointment so that they may begin to take this message to physicians later this quarter.

    接下來我想把電話交到較偏營運的部分,談談我們在美國的活動。我們已就 Zovirax 軟膏對銷售代表完成充分準備與訓練,使他們能在本季稍晚開始向醫師傳達此產品訊息。

  • In addition, we concluded our first full quarter of promoting Wellbutrin SR and the response continues to be very positive from both our partners at GSK and the physician community. Biovail Pharmaceuticals was able to maximize its revenue potential relating to the co-promotion arrangement with GSK for this product.

    此外,我們完成了首次完整季度的 Wellbutrin SR 推廣,而來自 GSK 合作夥伴與醫師社群的反應仍然非常正面。Biovail Pharmaceuticals 得以最大化與 GSK 就此產品共同推廣安排相關的營收潛力。

  • In March during the American College of Cardiology Meeting in Atlanta, Georgia, we had the opportunity to announce the acquisition of the family of products. This acquisition has strengthened our cardiovascular product line and allows us to leverage our expending sales force. We are currently transitioning from Solve and expect to begin promoting it to physicians by mid June.

    3 月在喬治亞州亞特蘭大的美國心臟病學會年會期間,我們有機會宣布收購產品家族。此項收購強化了我們的心血管產品線,並使我們能運用持續擴張的銷售團隊。我們目前正將自 Solve 轉移,並預期於 6 月中旬開始向醫師推廣。

  • In terms of our sales organization, we have completed extensive training programs all 800 reps on board and trained prior to the expected launch of Cardizem XL in the latter part of this year. With regards to Biovail Pharmaceuticals Canada, their first quarter performance was highlighted by continued growth momentum and their pull through revenue for the first quarter was higher than the same period last year and was led by strong Tiazac growth over the same first quarter performance last year.

    就我們的銷售組織而言,我們已完成大規模訓練計畫,讓 800 名業務代表全數到位並在預期於今年稍晚推出 Cardizem XL 前完成訓練。至於 Biovail Pharmaceuticals Canada,其第一季表現亮點為持續的成長動能;第一季的拉動式(pull-through)營收高於去年同期,並由 Tiazac 相較去年第一季的強勁成長所帶動。

  • Tiazac market share has improved over the first quarter a level of 27 percent to a level just above 34 percent in the first quarter of 2002. Celexa growth was also up and we are seeing good movement with Moniker based on its acceptance on several provincial formularies.

    Tiazac 的市占率在第一季由 27% 提升至 2002 年第一季略高於 34%。Celexa 的成長也有所提升;基於其被納入多個省級處方集(formularies),我們也看到 Moniker 有良好進展。

  • In R&D we are initiating two additional phase three studies in osteoarthritis related to our Tramadol submission. Biovail has Phase 3 clinical studies ongoing with respect to Buspirone ER, and Biovail has ongoing developmental programs underway related to a once daily version of Metformin.

    在研發方面,我們正針對與 Tramadol 申請案相關的骨關節炎啟動另外兩項第三期研究。Biovail 亦就 Buspirone ER 進行第三期臨床研究,同時也在推動與每日一次(once daily)版本 Metformin 相關的開發計畫。

  • All of these programs are progressing well and we expect results later this year at an early 2003. We see our investment in as very positive as it will enable access to different molecules, new formulation technology and new niche therapeutic areas. The new areas being oncology and virology. Our phase four trial in investigating the effectiveness of our chromo-therapeutic product Cardizem XL in controlling the rise in blood pressure during the critical morning hours against other competitive anti-hypertensive products in the marketplace are going very well and should conclude during the fourth quarter and first half of 2003.

    上述計畫進展良好,我們預期於今年稍晚至 2003 年初取得結果。我們認為對的投資非常正面,因其將使我們得以取得不同分子、新的製劑技術以及新的利基治療領域;新領域包括腫瘤學與病毒學。我們的第四期試驗正在評估我們的染色治療(chromo-therapeutic)產品 Cardizem XL,與市場上其他競爭性降壓產品相比,在關鍵清晨時段控制血壓上升的效果;試驗進展非常順利,預計於第四季及 2003 年上半年結束。

  • Our efforts in conjunction with XL have been very successful and we anticipate filing GSK and NDA for once daily in mid-year 2002. With this in mind, construction has already started on a significant addition to our manufacturing space at , Manitoba.

    我們與XL 相關的努力非常成功,並預期於 2002 年年中向 GSK 提交每日一次的 NDA 申請。基於此,,曼尼托巴的製造廠房擴建工程已開始動工。

  • We will utilize this facility to supply Bupropion in different strengths and package sizes. This expansion will provide additional capacity of over a billion units per year. And now I'd like to turn the call over to , Vice President of Finance for a review of our financials -- .

    我們將利用該設施供應不同劑量強度與包裝規格的 Bupropion。此次擴建將提供每年超過 10 億單位的額外產能。接下來我想把電話交給,財務副總裁,請他回顧我們的財務狀況——。

  • - Vice President of Finance

    - Vice President of Finance

  • Thank you, Bill, and good morning, everyone.

    謝謝你,Bill,各位早安。

  • I am pleased to describe to everyone Biovail's financial accomplishments for the first quarter of 2002. Biovail reports its financial results in U.S. dollars and under U.S. gap. All earnings per share information discussed today are on a diluted and post split basis.

    我很高興向各位說明 Biovail 在 2002 年第一季的財務成果。Biovail 以美元並依照美國公認會計原則(U.S. GAAP)報告其財務結果。今天討論的每股盈餘資訊皆以稀釋後且分割後(post split)基礎計算。

  • Canadian gap statements are available for shareholders upon request. Included in Biovail's results are the effects of Biovail's acquisition of the Cardizem brands effective January 1, 2001, the acquisition of from Solve Pharmaceutical effective March 2002 and Biovail's transaction with Glaxo Smith Kline, including the acquisition of the topical line effective January 1, 2002 and the co-promotion of Glaxo's Wellbutrin SR product in the United States.

    加拿大 GAAP 報表可應股東要求提供。Biovail 的結果包含以下交易影響:自 2001 年 1 月 1 日起生效之 Cardizem 品牌收購;自 2002 年 3 月起生效之自 Solve Pharmaceutical 收購;以及 Biovail 與 Glaxo Smith Kline 的交易,包括自 2002 年 1 月 1 日起生效之外用產品線收購,以及在美國共同推廣 Glaxo 的 Wellbutrin SR 產品。

  • On a consolidated basis, total revenues for the first quarter of 2002 were $155.3 million, reflecting an increase of 30 percent or $36 million from the 2001 first quarter level of $119.2 million. Net income for the quarter increased 82 percent and was $53.1 million or 32 cents per share versus $29.2 million or 20 cetns per share for the first quarter of 2001.

    以合併基礎計,2002 年第一季總營收為 1.553 億美元,較 2001 年第一季的 1.192 億美元增加 30%,即增加 3,600 萬美元。本季淨利增加 82%,達 5,310 萬美元或每股 0.32 美元;相較之下,2001 年第一季為 2,920 萬美元或每股 0.20 美元。

  • Now with respect to operating revenue by segment, net product sales revenue for the current quarter were $129.9 million versus $108.9 million for the equivalent 2001 period reflecting an increase of 19 percent. The growth in product sales revenue was driven primarily by sales of the recently acquired Zovirax and products as well as the Cardizem brands, which are all sold by Biovail Pharmaceuticals.

    接著就分部別營運收入而言,本季淨產品銷售收入為 1.299 億美元,較 2001 年同期的 1.089 億美元增加 19%。產品銷售收入的成長主要由近期收購的 Zovirax 與產品,以及 Cardizem 品牌的銷售所帶動;上述產品皆由 Biovail Pharmaceuticals 銷售。

  • Research and development revenues increased due to a higher level of third party research activity including developmental activities associated with once daily on behalf of and in association with Glaxo. Co-promotion, royalty and licensing revenue increased $10.9 million to $19.7 million for the first quarter of 2002.

    研發收入因第三方研究活動水準提高而增加,其中包括代表 Glaxo 並與其合作進行的每日一次(once daily)相關開發活動。共同推廣、權利金與授權收入在 2002 年第一季增加 1,090 萬美元至 1,970 萬美元。

  • The increase reflects the inclusion of a co-promotion revenue related to SR as well as co-promotion revenues associated with Celexa in Canada. The co-promotion revenues associated with Celexa were reclassified to the co-promotion royalty and licensing line to be consistent with the presentation of the SR co-promotion revenues. Gross margins were approximately 72.5 percent for the first quarter of 2002 versus 75.8 percent for the first quarter of 2001.

    此項增加反映納入與SR 相關的共同推廣收入,以及在加拿大與 Celexa 相關的共同推廣收入。與 Celexa 相關的共同推廣收入已重新分類至共同推廣、權利金與授權項下,以與SR 共同推廣收入的呈列方式一致。2002 年第一季毛利率約為 72.5%,相較 2001 年第一季為 75.8%。

  • The change in gross margins is primarily related to product sales mix. In particular Zovirax ointment margins are lower in comparison to other Biovail products. Additionally gross margins were impacted by the exclusion of co-promotion revenues that were previously accounted for under product sales. For the first quarter 2002, research and development expenses were $10.5 million and SG&A expenses were $39.3 million. The 47 percent increase in SG&A spending in 2001 first quarter versus Q1 2001 is primarily due to increases in head count and higher Biovail Pharmaceutical's USA promotional expenses.

    毛利率的變動主要與產品銷售組合有關。特別是,Zovirax 軟膏的毛利率相較於 Biovail 其他產品較低。此外,毛利率亦受到排除共同推廣收入的影響;該等收入先前係列入產品銷售中認列。2002 年第一季,研發費用為 1,050 萬美元,銷售、一般及行政(SG&A)費用為 3,930 萬美元。2002 年第一季相較於 2001 年第一季 SG&A 支出增加 47%,主要係因人員編制增加以及 Biovail Pharmaceutical's USA 推廣費用提高所致。

  • The increase in amortization expense of $1.9 million reflects the incremental expenses associated with the acquisition of the Zovirax ointment and product rights offset partially by the reduction in intangible asset values of Keftab and Dura-Vent and the elimination of goodwill amortization effective January 1, 2002 as a result of the adoption of Phase 142. Operating income of $57.2 million increased by 29 percent versus the prior year quarter of $44.4 million.

    攤銷費用增加 190 萬美元,反映收購 Zovirax 軟膏及產品權利所帶來的新增費用,部分被 Keftab 與 Dura-Vent 無形資產價值降低,以及因採用 Phase 142 自 2002 年 1 月 1 日起停止商譽攤銷所抵銷。營業利益為 5,720 萬美元,較前一年同期的 4,440 萬美元增加 29%。

  • First quarter 2002 cash flow from operations increased over 70 percent and was $111.3 million versus $65.3 million for the first quarter 2001. During the quarter, Biovail issued $400 million in aggregate principle amount of unsecured seven and seven-eighths senior subordinated notes. This security was assigned a BB- rating by Standard and Poor's.

    2002 年第一季營運活動現金流量增加逾 70%,達 1 億 1,130 萬美元,較 2001 年第一季的 6,530 萬美元為高。於本季期間,Biovail 發行總本金額 4 億美元之無擔保七又八分之七年期次順位優先票據。該證券由標準普爾評為 BB-。

  • Also during the quarter, Standard and Poor's raised Biovail's corporate credit and senior security debt rating to BB+ from BB. In addition to paying down outstanding amounts under Biovail's revolving term credit facility, Biovail paid Glaxo $133 million for the rights to the Zovirax ointment line and $94 million to Solve to acquire and HCT.

    同樣在本季期間,標準普爾將 Biovail 的公司信用評等及優先證券債務評等由 BB 調升至 BB+。除償還 Biovail 循環定期信貸融資項下之未償餘額外,Biovail 亦支付葛蘭素(Glaxo)1 億 3,300 萬美元以取得 Zovirax 軟膏產品線權利,並支付 Solve 9,400 萬美元以收購及HCT。

  • Biovail also invested $2.5 million in Prosion Viopharma and acquired U.S. exclusive marketing rights to Prosion's topical therapeutic product Fibrostat for scar management. Prosion will develop the product in return for royalties and fees subject to the attainment of certain milestones. Evidda defined its earnings before interest, taxes, depreciation and amortization increased 26 percent to $72.3 million for the quarter ended March 31, 2002 versus $57.4 million for the equivalence prior year period.

    Biovail 亦投資 250 萬美元於 Prosion Viopharma,並取得 Prosion 外用治療產品 Fibrostat(用於疤痕管理)在美國之獨家行銷權。Prosion 將負責開發該產品,作為交換,Biovail 將支付權利金及費用,惟須達成特定里程碑。Evidda 所定義之息前稅前折舊攤銷前盈餘(EBITDA)於截至 2002 年 3 月 31 日之季度增加 26% 至 7,230 萬美元,較前一年同期之 5,740 萬美元為高。

  • Evidda is a non-gap measure that does not have a standardized meaning and as such may not be comparable to similarly titled measures presented by other companies. Effective January 1, 2002 the company adopted Phase Statement 142, which eliminated the amortization of goodwill. Goodwill amortization of $1.6 million and diluted earnings per share of $.01 from the first quarter 2001 results net income and diluted earnings per share increased by 72 percent and 52 percent respectively for the first quarter 2002. This concludes my discussion regarding Biovail's first quarter 2002 performance and at this point I would like to open up the call for questions.

    Evidda 為一項非 GAAP 指標,並無標準化定義,因此可能無法與其他公司所呈列之同名指標相互比較。公司自 2002 年 1 月 1 日起採用 Phase Statement 142,取消商譽攤銷。2001 年第一季商譽攤銷為 160 萬美元,稀釋後每股盈餘為 0.01 美元。2002 年第一季之淨利及稀釋後每股盈餘分別增加 72% 與 52%。以上為我對 Biovail 2002 年第一季表現之說明,接下來我想開放電話會議進行提問。

  • Operator

    Operator

  • Thank you, sir. Ladies and gentlemen, at this time if research analysts currently covering the company have a question, you will need to press the one on your touch-tone phone and you will hear a tone acknowledging your request. Your questions will be taken in the order that they are received. If your questions have already been answered, you may remove yourself from the queue by pressing the pound key. In addition, if you are using a speakerphone, please pick up your handset before pressing the buttons. One moment for our first question. , please state your company name followed by your question.

    謝謝您,先生。各位女士、先生,此刻若目前有研究分析師正在追蹤本公司且有問題,請按下您的按鍵式電話上的 1,您將聽到提示音以確認您的請求。我們將依收到的順序回答問題。若您的問題已獲解答,您可按下井字鍵退出排隊。此外,若您使用擴音電話,請在按鍵前先拿起聽筒。請稍候,我們接第一個問題。,請先說明您的公司名稱,接著提出您的問題。

  • Yes. Good morning.

    是的。早安。

  • The question revolves around the upcoming American Society for Hypertension Meeting. I wanted to get a feel for what are your plans for the release of the phase three Cardizem XL clinical trial? And I understand you're actually going to be hosting the symposium at one point during that meeting and I was wondering if you could just discuss the opportunities for positioning Cardizem XL particularly since you're going to also see the release of the Pharmacia Convince clinical trial with a similarly delivered form of Verapamil, the nocturnal Verapamil formation. I was wondering if you could put a little context on that upcoming conference.

    問題與即將召開的美國高血壓學會(American Society for Hypertension)年會有關。我想了解你們對於第三期 Cardizem XL 臨床試驗結果發布的規劃為何?我也了解你們將在會議期間某個時段主辦一場專題研討會,我想請你們談談 Cardizem XL 的定位機會,特別是因為你們也將看到 Pharmacia 的 Convince 臨床試驗結果發布,該試驗使用類似的給藥形式——維拉帕米(Verapamil)的夜間給藥配方。我想請你們就這場即將到來的會議提供一些背景脈絡。

  • - Chairman

    - Chairman

  • Yeah. Hi, , it's Eugene here, and first of all I want to apologize for that little technical glitch that we had there.

    是的。嗨,,我是 Eugene。首先我要為剛才那個小小的技術問題向各位致歉。

  • There is going to be a number of activities at Ash this year, not just the post-year session and a symposium but at the same time it's our intention to also discuss and disclose the various phase four clinical trials that are ongoing with Cardizem XL versus other antihypertensives, so we're going to take the opportunity at that meeting to basically disclose virtually all of our clinical programs. Specifically on Ash and the questions you asked, I'll defer that to Bill Poole.

    今年在 Ash 會議上會有多項活動,不僅有會後場次與一場研討會;同時,我們也打算討論並揭露 Cardizem XL 與其他降壓藥之間正在進行的各項第四期臨床試驗。因此,我們將利用該會議的機會,基本上揭露幾乎所有我們的臨床計畫。就 Ash 以及您所提的問題,我會交由 Bill Poole 回答。

  • - President

    - President

  • Thanks, Eugene. I think I'll turn it over to Ken Howling, who is going to be coordinating that conference for us.

    謝謝你,Eugene。我想我會把問題交給 Ken Howling,他將為我們協調這次會議。

  • - Vice President of Finance

    - Vice President of Finance

  • Thanks. , a couple of things will take place. Certainly the day of the conference there will be a press release that goes out that will broadly disseminate the results of the trial, et cetera.

    謝謝。,將會有幾件事發生。當然,在會議當天會發布新聞稿,將試驗結果等資訊廣泛對外發布。

  • There are symposiums ongoing during the conference that we are participating in and we'll be talking about the product as well at the conference there will be a number of activities including something that's going on in the morning, something we're sponsoring as well, we intend to have a presentation of the data with one of the lead clinical investigators to present and provide some color on the data, that's scheduled for 1:30 in the afternoon that day, a number of different activities.

    會議期間我們也會參與持續進行的多場研討會,並在會中談到該產品;此外,會議上還會有多項活動,包括早上的一個活動,以及我們也贊助的一個活動。我們計畫安排由其中一位主要臨床研究者進行數據簡報,並就數據提供更多說明;該場次預定在當天下午 1:30 進行,還有多項不同活動。

  • In terms of positioning the product, I think the fact that the convinced data is coming out, you know, we believe that and we certainly hope that will be a positive. We believe the fact that there is more and more dialogue around the fact that Circadian rhythm is important in addressing patient's hypertension and medication dosing regimes. We think all of that is supportive in terms of assisting us with the launch of our Cardizem XL product.

    就產品定位而言,我認為 Convince 的數據即將公布這件事,我們相信——也當然希望——會是正面的。我們認為,圍繞「晝夜節律(Circadian rhythm)在處理患者高血壓與用藥劑量方案上很重要」的討論愈來愈多。我們認為這些都有助於支持我們推出 Cardizem XL 產品。

  • Thank you very much.

    非常感謝。

  • Operator

    Operator

  • . Please state your company name followed by your question.

    。請先說明您的公司名稱,接著提出您的問題。

  • Hi. Thanks. from UBS Warburg.

    嗨,謝謝。,來自 UBS Warburg。

  • Just a couple of hopefully short and simple questions here. I guess the $50 million payments on SR, should we assume those are spread fairly evenly across the four quarters of '02? And second, I guess on Zovirax sales, I doubt you want to bring that up, but were you satisfied with the sales for the quarter on that product? And I guess third, any update on any clinical data or clinical presentations on flash dose Prozac clinical trials? Thanks.

    我這裡有幾個希望簡短且容易的問題。第一,關於SR 的 5,000 萬美元付款,我們是否應假設這些款項在 2002 年四個季度之間大致平均分攤?第二,關於 Zovirax 的銷售,我猜你們不太想提,但你們對本季該產品的銷售表現滿意嗎?第三,關於 flash dose Prozac 臨床試驗,有沒有任何臨床數據或臨床發表的最新進展?謝謝。

  • - President

    - President

  • In terms of the $50 million, , the, if you will, how that is earned is based on detailing activity. You know, it's not a fixed piece, it's not a straight-line allocation over four quarters. It is in fact the opportunity to earn up to $10 million over five quarters and that's certainly something that has to be earned, and is earned, we believe, will be earned through the detailing of the products.

    就 5,000 萬美元而言,,其取得方式(如果你願意這麼說)是以拜訪推廣(detailing)活動為基礎。你知道,這不是固定金額,也不是在四個季度之間直線式分攤。實際上,這是於五個季度內最多可賺取 1,000 萬美元的機會,而這確實需要透過產品的拜訪推廣來賺取;我們相信也將能透過拜訪推廣而賺取。

  • So if we're as successful as we expect we will be on detailing, it will be roughly $10 million per quarter over a five-quarter period. Zovirax sales of course we just acquired the product. We are anticipating getting samples from GSK later this quarter, such that we'll be able to actively get out and detail the product to physicians.

    因此,如果我們在拜訪推廣方面如預期般成功,則在五個季度期間大約每季 1,000 萬美元。至於 Zovirax 的銷售,當然我們才剛收購該產品。我們預期本季稍晚會從 GSK 取得樣品,如此我們就能積極向醫師進行產品拜訪推廣。

  • Of course we believe the sampling will enable us to create greater awareness for the product and increase the market share and prescription trends for the product but until that time, we're happy with the performance of the product. But again, until we have the samples, which we expect later this quarter, you know, we'll be supporting the product that way at that time. In terms of clinical data, on flash dose, be it Prozac or other products, we have not released that clinical data. We do expect to be filing a flash dose version of Paroxetine or Prozac in the middle part of this year.

    當然,我們相信提供樣品將使我們能提高對該產品的認知度,並提升其市占率與處方趨勢;但在那之前,我們對該產品的表現感到滿意。不過再次強調,在我們取得樣品之前——我們預期在本季稍晚——屆時我們會以那種方式來支持該產品。至於臨床數據,關於 flash dose,不論是 Prozac 或其他產品,我們尚未發布該臨床數據。我們確實預期將在今年年中提交 Paroxetine 或 Prozac 的 flash dose 版本申請。

  • Paroxetine would be .

    Paroxetine 會是。

  • - President

    - President

  • I'm sorry on the Prozac product.

    很抱歉,關於 Prozac 產品。

  • I thought flash dose Prozac was already filed.

    我以為快閃劑量的 Prozac 已經送件了。

  • - President

    - President

  • Yeah, I'm confused too. We haven't released the clinical data on the Prozac.

    是的,我也很困惑。我們尚未公布 Prozac 的臨床數據。

  • Again, there are no plans right now at some venue, I guess you haven't decided yet how you're going to release that clinical data.

    再說一次,目前在某個場合沒有任何計畫;我想你們還沒決定要如何發布那些臨床數據。

  • - President

    - President

  • To my knowledge, that's correct.

    就我所知,沒錯。

  • OK. Just one other quick question, if I could just sneak one more in. You know on the conference call yesterday mentioned that within their internal budgets, you know, they're basically baking in a July generic Tiazac launch, I'm wondering if you can just remind us again what your plans are for and I guess in relation to your earnings guidance for this year, if you could just discuss that a little bit further. Thanks.

    好的。再一個很快的問題,如果我可以再偷偷問一個。你知道在昨天的電話會議上提到,在他們的內部預算中,基本上已經把 7 月推出學名藥 Tiazac 的上市納入考量;我想請你再提醒我們一次你們的計畫是什麼,以及我想就你們今年的盈餘指引而言,能否再多談一點。謝謝。

  • - President

    - President

  • Sure, happy to. You know, as we have anticipated, I think everyone has anticipated that at some point there would be a launch of generic Tiazac. We've already based that into models and I believe most, if not all analysts have also baked that in. I think most people have assumed a Q3 launch of generic Tiazac by ourselves, by and we would expect that overall our Tiazac franchise for 2002 would be close to or slightly below the level of revenues we saw for the Tiazac franchise in 2001.

    當然,很樂意。你知道,正如我們所預期的,我想大家都預期在某個時間點會有學名藥 Tiazac 上市。我們已經把這點納入模型,我相信大多數(如果不是全部)分析師也都已經把它納入。我想多數人假設我們自己會在第三季推出學名藥 Tiazac,由推出;而我們預期 2002 年整體 Tiazac 產品線的營收會接近或略低於 2001 年 Tiazac 產品線的營收水準。

  • OK. All right. Thank you.

    好的。好。謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,接著提出問題。

  • I'm at JP Morgan and my first question is, can you remind us which of the products show the most seasonality and why there is always that sequential dip in your top line going from Q4 to Q1? And also, , if you can just do your usual rough breakout by percentages for your different franchises so we can have some idea of which divisions did best?

    我在 JP Morgan。我的第一個問題是:你能提醒我們哪些產品呈現最明顯的季節性,以及為什麼你們的營收從第四季到第一季總是會出現連續性的下滑嗎?另外,,如果你能照慣例用百分比大致拆分你們不同產品線的占比,讓我們對哪些部門表現最好有個概念?

  • - Vice President of Finance

    - Vice President of Finance

  • Sure. I'll jump in with the product sales mix. I'll give you percentages, and this is a breakdown of the product sales revenue line.

    當然。我先說產品銷售組合。我會給你百分比,這是產品銷售收入這一行的拆分。

  • Tiazac was roughly 5 percent to 10 percent of total product sales.

    Tiazac 約占總產品銷售的 5% 到 10%。

  • Cardizem was approximately 40 percent.

    Cardizem 約占 40%。

  • Generic products were between 25 percent to 30 percent.

    學名藥產品約占 25% 到 30%。

  • Our Canadian business was less than 5 percent of total product sales.

    我們的加拿大業務占總產品銷售不到 5%。

  • Biovail Pharmaceutical's USA including the , Zovirax acquisitions was between 20 percent and 25 percent and other revenues, Neurotrend, Melvyn, et cetera, were less than one percent.

    Biovail Pharmaceutical 的美國業務(包含、Zovirax 的收購)約占 20% 到 25%;其他收入(Neurotrend、Melvyn 等)不到 1%。

  • Great. And the explanation on the seasonality?

    很好。那季節性的解釋呢?

  • - President

    - President

  • , do you want me to jump in on that?

    , 你要我來回答這個嗎?

  • - Vice President of Finance

    - Vice President of Finance

  • Yes, please. , really, the seasonality really ties into year-end expectations by the wholesalers. It's been something that has plagued the industry for a number of years and that is anticipation of price increases and inventory adjustments. It really has nothing more than that involved with it. We tried to smooth it out as best we can and sometimes we're more successful than others. But that usually is the answer to that question.

    是的,麻煩。, 其實,季節性主要與批發商對年底的預期有關。這是多年來困擾整個產業的問題,也就是對漲價的預期以及庫存調整。基本上就只有這些因素。我們盡可能把它平滑化,有時做得比較成功,有時則不然。但通常答案就是這樣。

  • OK. And then ...

    好的。然後……

  • - Vice President of Finance

    - Vice President of Finance

  • , and I think if you looked at historically the numbers over the last four or five years, we've always had that same trend and it started back in the days when was our largest client ordering Tiazac and there was always a significant third and fourth quarter fill orders.

    , 而且我想如果你回頭看過去四、五年的歷史數字,我們一直都有同樣的趨勢;它始於還是我們最大客戶、訂購 Tiazac 的年代,當時第三季和第四季總會有顯著的補庫訂單。

  • It's more from wholesaler buying patterns or in that case Forrest buying patterns than it is for true fluctuations and user demand for your products.

    這更多是批發商的採購模式(或在那個案例中 Forrest 的採購模式),而不是真正反映你們產品終端使用者需求的波動。

  • - Vice President of Finance

    - Vice President of Finance

  • That's correct.

    沒錯。

  • And my next question, probably more for is just, I know you gave a little bit of an update on the progress of the sales force, but once you have everybody on board, maybe you can go over how you plan to prioritize the details to physicians of all the different products that you have right now, Wellbutrin, Zovirax, , are there going to be two different sales forces out of that 800 or is it going to be one big 800 rep sales force?

    我的下一個問題,可能比較是問:我知道你剛才稍微更新了銷售團隊的進度,但等你們人員都到位後,能否談談你們打算如何在目前所有不同產品之間,優先安排對醫師的拜訪與推廣?像是 Wellbutrin、Zovirax、等。那 800 人會分成兩支不同的銷售隊伍,還是會是一支 800 人的大型業務團隊?

  • - President

    - President

  • Yes, I will be happy to talk about that. Our plan right now will be to certainly concentrate on XL with our full sales organization and then we'll look at category two or position two, position three for our other mix of products and that will of course bring into mind the seasonality of some of our products.

    是的,我很樂意談這個。我們目前的計畫是,當然會用我們完整的銷售組織把重點放在 XL 上;接著我們會看第二類或第二順位、第三順位,來安排其他產品組合,而這當然也會把部分產品的季節性納入考量。

  • And then lastly, especially on , how are you going to market that against all the big competitors out there? And do you think that Merck's results with Cozaar's life trial is going to help or hurt 's potential?

    最後一個問題,特別是關於:你們要如何在市場上與那些大型競爭對手對打?你認為 Merck 在 Cozaar 的 LIFE 試驗結果,會幫助還是傷害的潛力?

  • - President

    - President

  • I can't say for certain how Merck's data will help or hurt for sure. We are pulling together the marketing plans for and be happy to share them with you at a later date. But right, for now, I would prefer to hold off on the details of our plan. We do think we're putting together a very strong program for positioning it in the marketplace and I believe that we will be able to make some good in-roads with this product. But I would not want at this point to get into the details of that promotional program.

    我無法確定 Merck 的數據會如何幫助或傷害。我們正在彙整的行銷計畫,之後很樂意在適當時候與你分享。但就目前而言,我希望先不談我們計畫的細節。我們確實認為我們正在為擬定一個非常強而有力的方案,把它定位在市場中;我相信我們能用這個產品取得一些不錯的進展。但此時我不想深入談那個推廣計畫的細節。

  • Great quarter, guys. Thanks.

    這一季表現很棒,各位。謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,接著提出問題。

  • - President

    - President

  • , are you there?

    , 你在線上嗎?

  • Operator

    Operator

  • Actually sir, he just disconnected from conference. , please state your company name followed by your question.

    先生,其實他剛剛已經從會議中斷線了。, 請先說明您的公司名稱,接著提出問題。

  • Sure. RBC Capital Markets. Just a couple of housekeeping items first, . With respect to R&D, it seemed to be a little bit lower than anticipated this quarter, I was wondering if you could talk about if you still expected to be between 8 percent to 10 percent for the year. Same thing on the tax rate and why there was a decrease in current assets and then maybe a larger item for Eugene just with respect to plans in the future in terms of the acquisition of future products. If the focus is going to be on combination types products patents versus maybe what you've been doing in the past from a strategic perspective. Thanks.

    好的。RBC Capital Markets。先問幾個例行事項,。關於研發費用,本季看起來比預期稍低;我想請問你們是否仍預期全年會落在 8% 到 10%?稅率也是同樣問題,以及為什麼流動資產會下降;另外可能有個比較大的問題要問 Eugene:關於未來產品收購的規劃,你們的重點是否會轉向以組合型產品的專利為主,而不是過去那種策略方向?謝謝。

  • - Vice President of Finance

    - Vice President of Finance

  • I'll start off, I guess. , absolutely we do expect R&D spending on the year to be in that eight percent to 10 percent range. Tax rate again is as expected, it was right around seven percent. Our guidance has been in that range seven percent to eight percent and creeping up as a result of acquisitions and a higher propensity of our revenues occurring in the US marketplace but at the present time, it's still in that seven percent, seven percent to eight percent range. What was the third, ?

    我先開始吧。, 我們確實預期全年研發支出會落在 8% 到 10% 的區間。稅率也如預期,約在 7% 左右;我們的指引一直在 7% 到 8% 的範圍內,並會因收購以及我們收入在美國市場占比提高而逐步上升,但目前仍在 7% 到 8% 的區間。第三個問題是什麼,?

  • Oh, just current assets, there was a significant drop that contributed to the cash flow of this quarter. I was just wondering what that related to?

    喔,就是流動資產。本季有顯著下降,對本季現金流有貢獻。我想知道那主要是什麼原因?

  • - Vice President of Finance

    - Vice President of Finance

  • The biggest difference is in accounts receivable.

    最大的差異在應收帳款。

  • Great.

    很好。

  • - Chairman

    - Chairman

  • OK, now, . Just on the plans for the future products, we are considering a number of new product ideas. Specifically you can see what we recently announced with the investment into .

    好的,現在,。至於未來產品的規劃,我們正在考慮多個新產品構想。具體而言,你可以看到我們最近宣布對的投資。

  • There are a half a dozen product ideas that are being pursued. We are also pursuing the whole concept, a number of combination products, specifically in the cardiovascular field. The one caution there is that they are very complicated clinical trials, very expensive and we are still assessing on a number of fronts the physician acceptability of some of these ideas. But we're certainly pursuing a number of combination product ideas and we hope to have something coming forth pretty soon.

    目前大約有半打產品構想正在推進。我們也在推動整個概念:多種組合型產品,特別是在心血管領域。需要提醒的是,這些臨床試驗非常複雜、成本很高;我們也仍在多個面向評估醫師對其中一些構想的接受度。但我們確實在推進多個組合產品的構想,並希望很快能有一些成果推出。

  • OK. Great. And just finally on the Buspirone, those results should be out when, exactly?

    好的,很好。最後關於 Buspirone,那些結果確切會在什麼時候出來?

  • - Vice President of Finance

    - Vice President of Finance

  • Those trials we expect to be complete at the end of this year. So at least internally we expect to have them end of this year, early next. Exactly when we would share that data is something we'll decide in the future.

    我們預期那些試驗會在今年底完成。因此至少在內部,我們預期今年底、明年初會完成。至於我們何時會對外分享那些數據,未來再決定。

  • Thank you.

    謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,接著提出問題。

  • Yeah, Bank America Securities. One, can you give us a breakdown of product sales? And two, can you at least give us, I know you broke out the product sales categories, but some sense of the growth rate between the various categories so we know where the growth is coming from?

    是的,美國銀行證券。第一,您能否提供產品銷售的明細?第二,您至少能否給我們一些資訊——我知道您已經把產品銷售類別拆開了——但能否讓我們了解各類別之間的成長率,好讓我們知道成長是從哪裡來的?

  • - Vice President of Finance

    - Vice President of Finance

  • Yeah, I can give you the product sales breakdown again . The percentages I'm about to give you are percentages of the total product sales line, not total revenues but product sale. Tiazac about eight percent to 10 percent.

    可以,我可以再把產品銷售的拆分提供一次。我接下來要給的百分比,是占「產品銷售」這一行的百分比,不是占總營收,而是占產品銷售。Tiazac 約占 8% 到 10%。

  • And that was on how much year over year?

    那年對年大約是多少?

  • - Vice President of Finance

    - Vice President of Finance

  • I don't have the growth rates exactly in front of me. That historical information of course is available and I can, you know, talk to you off line. Cardizem represents approximately 40 percent. Generic products were in a range of 25 percent to 30 percent. Canadian business was under 5 percent. Biovail Pharmaceuticals USA was in the range of 20 percent to 25 percent and other , et cetera, less than one percent.

    我手邊沒有精確的成長率數字。當然,那些歷史資訊是有的,我可以,你知道的,私下再跟你談。Cardizem 約占 40%。學名藥產品約在 25% 到 30% 的區間。加拿大業務低於 5%。Biovail Pharmaceuticals USA 約在 20% 到 25% 的區間,其他等等,低於 1%。

  • OK. I hate to bring up a sore subject obviously, but there are rumors going around that the Canadian regulatory authorities are also looking at your patent activities, is that true?

    好的。我很不想提這個顯然是敏感的話題,但外面有傳聞說加拿大的監管機關也在檢視你們的專利活動,這是真的嗎?

  • - President

    - President

  • No. We aren't aware of any kind of regulatory body of any sort in Canada looking at any patent activities. The only thing we do have is a patent litigation ongoing with a company that has filed a Tiazac generic, but that is a standard straightforward patent litigation.

    不是。我們並不知道加拿大有任何形式的監管機構在檢視任何專利活動。我們唯一有的是,與一家已提交 Tiazac 學名藥申請的公司之間正在進行專利訴訟,但那是標準、直接的專利訴訟。

  • OK. Thank you.

    好的,謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,接著提出問題。

  • Yes, Merrill Lynch. This may be a question really for , but in his absence, maybe . Just in terms of the Federal Trade Commission settlement that you announced recently, there is a requirement to divest the Dove patent and also a requirement to consult with the FDC prior to certain patent filings. And I'm wondering, can you maybe give us a sense of how this impedes or doesn't impede your business activities going forward on both of those issues?

    是的,美林。這個問題可能真的要問,但他不在的話,也許可以回答。就你們最近宣布的聯邦貿易委員會(FTC)和解而言,其中要求剝離 Dove 專利,並且要求在某些專利申請前先與 FDC 諮詢。我想請問,你們能否讓我們了解,這兩點在未來會如何影響或不影響你們的業務活動?

  • - Chairman

    - Chairman

  • Sure. We actually have on standby in case a much more complex question came up. But I can answer those because they're pretty straightforward. There is a requirement to divest the Dove patent or covert it into a non-exclusive patent. But the main purpose of that was of course to drop the patent litigation and therefore remove any kind of regulatory illegal hurtle for the introduction of a generic Tiazac.

    當然。我們其實讓待命,以防出現更複雜的問題。不過這兩點我可以回答,因為相當直接。確實有要求要剝離 Dove 專利,或將其轉為非專屬專利。但其主要目的當然是撤下專利訴訟,從而移除任何對引進 Tiazac 學名藥的監管或法律障礙。

  • Would that prevent you from, for example, working on other Diltiazem combinations?

    那會不會例如阻止你們研發其他 Diltiazem 的複方?

  • - Chairman

    - Chairman

  • No, absolutely not. No. No. Nothing like that. It's specific to the Dove patent. So we need to divest ourselves.

    不,絕對不會。不,不會,完全不是那樣。它只針對 Dove 專利。所以我們需要把它剝離出去。

  • With respect to any future activity, it's very, very remote that we would even have to do this. But it's a simple notification, very similar to an HSR, a Hart Skar Rodino notification, it has to go to the FDC. In the event that we were to acquire a patent for an already approved product where an ANDA has already been approved, anytime going forward when we do acquire products, virtually every single one of those require an HSR approval anyway. Anything over a $50 million threshold requires it, so it doesn't impact us at all other than a notification that requires a 30 day review and a possible 30 day extension.

    至於任何未來的活動,我們幾乎不太可能真的需要做這件事。但它只是簡單的通知,非常類似 HSR(Hart-Scott-Rodino)通知,需要送交 FDC。若未來我們要取得一個已核准產品的專利,而該產品的 ANDA 已經核准,則往後任何時候我們收購產品,幾乎每一件本來就需要 HSR 核准。任何超過 5,000 萬美元門檻的交易都需要,所以除了需要一個通知、30 天審查以及可能再延長 30 天之外,對我們完全沒有影響。

  • Thanks.

    謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,接著提出問題。

  • National Bank Financial. Just a quick couple of housekeeping questions. With respect to the quarter, , were there any generic Tiazac shipments this quarter or are you expecting any in the second quarter in preparation for a July launch of generic Tiazac?

    National Bank Financial。我有幾個簡短的例行問題。就本季而言,,本季是否有出貨學名 Tiazac?或者你們是否預期第二季會有出貨,以便為 7 月推出學名 Tiazac 做準備?

  • - Vice President of Finance

    - Vice President of Finance

  • Well, I won't speak about our strategies going forward, but certainly in Q1 of this year 2002, we did not have any shipments of generic Tiazac, no.

    嗯,我不談我們未來的策略,但可以確定的是,在今年 2002 年第一季,我們沒有任何學名 Tiazac 的出貨,沒有。

  • And then, anything on the FDA with respect to generic Pericardia or Adalat? And is there any litigation ongoing there between you and the brand companies?

    另外,關於學名 Pericardia 或 Adalat 的 FDA 進度有什麼消息嗎?你們與原廠之間是否有任何訴訟正在進行?

  • - Vice President of Finance

    - Vice President of Finance

  • There is the standard ongoing patent infringement litigation between the innovators for Pericardia XL and Adalat CC, that litigation continues. But we do expect to have the 90 mg dosage strengths for both of those products in the marketplace later this year.

    針對 Pericardia XL 與 Adalat CC,與創新藥廠之間有標準的專利侵權訴訟仍在進行。但我們預期今年稍晚會把這兩個產品的 90 mg 劑量規格推向市場。

  • And then just finally, I think for , on the Tramadol, , perhaps I was mistaken, but I thought I heard you say that you just started a phase three on Tramadol for osteo-arthritis, is that correct?

    最後,我想是問的,關於 Tramadol,,也許我聽錯了,但我以為我聽到你說你們剛開始針對骨關節炎的 Tramadol 第三期試驗,對嗎?

  • - President

    - President

  • Yes, , that is correct.

    是的,,沒錯。

  • Was that trial not already done? And my understanding at least from the last conference call was that the trials that you were currently ongoing with the Tramadol were just sort of long-term, you know, a few patients with short-term dosing, a few patients with longer term dosing, that was all that needed to be done. Is this a change from last quarter?

    那個試驗不是已經做完了嗎?而且我對上次電話會議的理解是,你們當時正在進行的 Tramadol 試驗只是一些長期的——你知道的——少數病人的短期給藥、少數病人的較長期給藥,這些就是需要完成的部分。這和上季相比有變化嗎?

  • - President

    - President

  • No. I don't believe it's a change. What we're doing is two studies on Tramadol. They are in place and there has not been a change.

    不,我不認為有變化。我們在 Tramadol 上做的是兩項研究。它們都已在進行中,並沒有改變。

  • - Vice President of Finance

    - Vice President of Finance

  • Yeah, , we've already completed, I think we've announced that two clinical trials. There is an additional two. One of them, well, first thing is first, we need to have the absolute number of subjects that have gone through clinical trials up to 1,500. And that's in line with ICH guidelines, so these are extended trials or we've expanded on these trials to meet those requirements. So, no, since the last time we talked, nothing has changed.

    是的,,我們已經完成了——我想我們也已宣布——兩項臨床試驗。另外還有兩項。首先,我們需要讓累計進入臨床試驗的受試者絕對人數達到 1,500 人,這符合 ICH 指引,所以這些是延伸試驗,或是我們擴大了這些試驗以符合那些要求。因此,不,從上次我們談到現在,沒有任何改變。

  • OK. And are those still expected to be complete by the first quarter of next year?

    好的。那這些仍預期在明年第一季完成嗎?

  • - Vice President of Finance

    - Vice President of Finance

  • Yes, they are. I mean, if all the patient enrollment keeps moving along like we expect it to, we should have those completed by the first quarter.

    是的,仍然是。我是說,如果病人收案持續如我們預期地推進,我們應該能在第一季完成。

  • - President

    - President

  • One other comment, , about this July Tiazac launch, I just want to caution you. I believe the comment that came from was a July launch potentially of their generic. I don't believe, or we don't believe that there is going to be a July launch of Tiazac generic. It may be later in the year, but you know, for budgetary purposes we put it in, but I just, I wouldn't count on it happening at that time.

    另外一點,,關於這個 7 月的 Tiazac 上市,我想提醒你。我相信的說法是他們的學名藥可能在 7 月推出。我不認為——或我們不認為——7 月會推出學名 Tiazac。可能會在今年稍晚,但你知道的,為了預算目的我們把它放進去,但我只是想說,我不會指望它在那個時間點發生。

  • OK. And then just on the Tramadol , of the 1,500 patients, can you give us sort of a sense of where you are at with respect to enrollment?

    好的。那再回到 Tramadol,在 1,500 名病人中,你能否大概說一下目前收案進度到哪裡了?

  • - Chairman

    - Chairman

  • I think we're over 1,000, but I can't be sure. Don't take me on that number. But it's well along because I think the first couple had 500 or 600 or 700 already and then we started a new trial and then there is a further trial. And the other thing I just want to mention on Tramadol is the fact that we're looking for expanded indications as well. So there is multiple indications that are being pursued through these trials.

    我想已經超過 1,000 人,但我不敢確定。不要把那個數字當作我給的定論。不過進度已經很靠前,因為我記得前面幾個試驗已經有 500 或 600 或 700 人,然後我們又啟動了一個新試驗,接著還有另一個試驗。另外我也想提一下 Tramadol 的部分,我們也在尋求擴大適應症。所以這些試驗同時在推進多個適應症。

  • OK. Great. Thanks you.

    好的,很好。謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,接著提出問題。

  • Thanks very much, it's from Goldman Sachs. With respect to the pre-launch promotion ahead of Cardizem XL, could you give us some guidance as to if you've begun to spend for it yet and how you see that unfolding over the course of the year? And additionally with respect to the 500 rep sales force expansion you've targeted, I may have missed it earlier but could you update us on where you stand in terms of the hiring of new reps?

    非常感謝,我是高盛的。關於 Cardizem XL 上市前的預熱推廣,你能否指引我們:你們是否已開始為此投入費用,以及你們如何看待這在今年內的推進節奏?另外,關於你們目標擴編到 500 名業務代表的銷售團隊,我可能前面漏聽了,你能否更新一下目前新業務代表的招募進度?

  • - Chairman

    - Chairman

  • Sure. I'll let discuss that, , but one thing I can tell you, yes, we are spending money already on pre-launch activities. There is all sorts of monies being spent on sales and marketing plans being implemented, definitely we're spending money there. , why don't you walk through the sales force expansion?

    當然。我會讓來談這個,,但我可以先告訴你,是的,我們已經在上市前活動上花錢了。各種資金都在投入,用於銷售與行銷計畫的落地執行,我們確實在那方面花錢。,你來帶大家走一下銷售團隊擴編的情況,好嗎?

  • - President

    - President

  • Not a problem. Thanks, Eugene. , with regards to our expansion, it's going extremely well. We've just concluded a training class just a week ago. We have another group coming in in another three weeks. We're absolutely on schedule so it's going very well, that's all I can tell you. We're very pleased with the progress and the quality and caliber of the individuals that we're bringing in.

    沒問題。謝謝你,Eugene。, 關於我們的擴張,進展非常順利。我們就在一週前剛結束一個培訓班。再過三週還會有另一批人進來。我們完全按計畫進行,所以進展很好,這就是我能告訴你的。我們對進度以及我們招募進來的人員素質與水準都非常滿意。

  • Well, that's excellent . Can you give us a sense for how many completed the training class?

    嗯,那太好了. 你能讓我們了解一下有多少人完成了培訓班嗎?

  • - President

    - President

  • I can tell you that in the first training class that we had two weeks ago, there were in excess of 150 people.

    我可以告訴你,在我們兩週前的第一個培訓班中,人數超過150人。

  • Terrific. With respect to once daily, I know this NDA filing is in Glaxo's hands right now, but they indicated on their conference call that they thought the filing would take place in the second half of 2002 and I think when you signed the deal with Glaxo last October, you originally expected it to take place in the second quarter. Can you give us a little clearer picture on what's happening with respect to that filing?

    太棒了。關於每日一次,我知道這份NDA申請目前在葛蘭素(Glaxo)手上,但他們在電話會議上表示,他們認為申請會在2002年下半年提出;而我記得你們去年10月與葛蘭素簽約時,原本預期會在第二季提出。你能更清楚說明一下這項申請目前的狀況嗎?

  • - Chairman

    - Chairman

  • Yeah, we can because we have, you'll use as late as last week, but I can tell you there is still some questions that we're waiting for feedback back from the FDA, but when we talk about second quarter, they're talking second half, we are literally we are straddling those two quarters and that's kind of our timing.

    可以,因為我們一直有在追蹤;你可以說直到上週都還在進行。不過我可以告訴你,仍有一些問題在等待FDA回覆。至於我們談第二季、他們談下半年,實際上我們就是跨在這兩個季度之間,時間點大概就是這樣。

  • Now, it may be advantageous to wait an additional 60 days for further data to file all at once since they control that filing, they make the decision as to how they're going to proceed on that. I can tell you that the expectation though for a review is approximately ten months so as far as a launch date of that product, although we can't talk specifically because again these are GSK plans, it really doesn't impact the launch date for it and certainly doesn't impact our expectation of manufacturing for next year. Just a little more on that, we are expecting within the next 60 days and certainly by our next conference call to begin providing some guidance as to the manufacturing revenues that we expect in 2003 from this product and those manufacturing revenues we expect to start as early as the second quarter in anticipation of a launch in the latter half of the year.

    另外,或許等再多60天、取得更多數據後一次性送件會更有利;因為他們掌控該申請,由他們決定要如何推進。我可以告訴你,審查期的預期大約是10個月,所以就該產品的上市時間而言,雖然我們無法具體談(因為這畢竟是GSK的計畫),但這其實不會影響上市時點,當然也不會影響我們對明年製造的預期。再補充一點,我們預期在未來60天內、且最遲在下一次電話會議前,開始提供一些指引,說明我們預期在2003年從該產品取得的製造收入;而這些製造收入預期最早可在第二季開始認列,以配合下半年上市的準備。

  • So I can tell you that just touched on it, we were dramatically expanding our manufacturing facilities to accommodate that product launch both in Steinback and down in Dorado. So we're well on our way and that's basically the discrepancy, you're talking about a straddling of the quarters.

    所以我可以告訴你,剛剛也提到,我們正在大幅擴充製造設施,以因應該產品上市,包含Steinback以及Dorado那邊。我們進展順利,基本上差異就在於你所說的跨季度。

  • That's great. Thanks for clarifying that. On the generic side, I know that you file an ANDA for generic Tegretol XR in January of 2001. Do you have any update on how that's progressing with the FDA and if this will be out licensed to Teva?

    太好了。謝謝你澄清。關於學名藥方面,我知道你們在2001年1月為Tegretol XR學名藥提交了ANDA。你能更新一下與FDA的進度嗎?以及這個產品是否會授權給Teva?

  • - Chairman

    - Chairman

  • Yeah. We expect approval for that product pretty soon. We will not be licensing that out to Teva. We are in discussions with multiple parties on the licensing of the product.

    可以。我們預期該產品很快就會獲得核准。我們不會把它授權給Teva。我們正在與多方洽談該產品的授權。

  • Great. And then one last question, if you wouldn't mind just quickly running through the timelines for the NDA filings now for flash dose Paroxetine, Zovirax cream, Tramadol once daily, Buspirone one daily and Metformin once day, that would be great. Remember all of those?

    很好。最後一個問題,如果你不介意,能否快速帶我們過一下目前各項NDA申請的時程:速溶劑型Paroxetine、Zovirax乳膏、每日一次Tramadol、每日一次Buspirone,以及每日一次Metformin。你都記得吧?

  • - Chairman

    - Chairman

  • Let's go through that one more time. The Zovirax cream, , when was that ...

    我們再過一遍。Zovirax乳膏,, 那個是什麼時候……

  • - President

    - President

  • The Zovirax, the virus cream has already been filed.

    Zovirax,那個病毒乳膏已經送件了。

  • Great.

    太好了。

  • - Chairman

    - Chairman

  • The Tramadol we're expecting the first half of next year and had asked earlier whether, if we complete the trial by the first quarter it's going to be a first half filing. Which other ones did you want to walk through?

    Tramadol我們預期在明年上半年,且你先前問過,如果我們在第一季完成試驗,是否就會在上半年送件。你還想要我再說明哪些?

  • Buspirone. I think we were looking for something later this year.

    Buspirone。我記得我們原本看的是今年稍晚。

  • - Chairman

    - Chairman

  • Yeah, assuming again that the clinical trials are completed and of course whether the clinical trials on Buspirone are successful, then we would expect an early 2003 filing. And again, that one we have to be very cautious about because it is a depression trial and those are a little riskier than the Tramadol and certainly the Zovirax ones.

    對,前提仍是臨床試驗完成,當然也要看Buspirone的臨床試驗是否成功;若順利,我們預期在2003年初送件。再者,這個我們必須非常謹慎,因為它是憂鬱症試驗,風險比Tramadol高一些,當然也比Zovirax那幾個更具風險。

  • Flash dose Paroxetine, I think that we've seen some slippage in that, I think we originally expected it in the first quarter. Do you think now it will come in in the third or fourth quarter of this year?

    速溶劑型Paroxetine,我想我們看到一些延後;我記得原本預期在第一季。你現在認為會落在今年第三或第四季嗎?

  • - Chairman

    - Chairman

  • Yeah, definitely. That's all we're doing is just making sure that all of the data, we're doing more than we have to make it an absolutely perfect submission, a perfected submission.

    是的,確實如此。我們所做的就是確保所有數據都到位;我們做得比要求更多,務求提交一份絕對完美的申請,一份完善的申請。

  • Great. And then just lastly on Metformin once daily, I know these are longer trials then average, can you give us a sense of when you think an NDA filing could take place for that product?

    很好。最後關於每日一次Metformin,我知道這些試驗比平均更長,你能否讓我們了解一下你認為該產品何時可能提交NDA?

  • - Chairman

    - Chairman

  • We're had to prioritize all of our products, you know, there is only so many clinical trials that we can do at any one time and as you I guess heard that we've got, you know, we've got three phase fours on Cardizem. We have two on Tramadol. We have Buspirone trials going. So we've basically prioritized those products. This product, you know, is an important one but we're looking at a 2003 timeframe for that. It's a question of how much we can do and how much we can spend in any one year. So we've tried to spread out that spend and we're looking at 2003 for that product.

    我們必須對所有產品排定優先順序,你知道,同一時間我們能做的臨床試驗數量有限;而且你大概也聽到,我們在Cardizem上有三個第四期試驗,Tramadol有兩個,Buspirone的試驗也在進行。所以我們基本上已經把這些產品排好優先順序。這個產品很重要,但我們看的是2003年的時間框架。問題在於我們一年之內能做多少、能花多少。所以我們試著把支出分散開來,這個產品我們看2003年。

  • Late '03, early '03?

    2003年末,還是2003年初?

  • - Chairman

    - Chairman

  • I would say mid to late.

    我會說是年中到年底。

  • OK. Thank you, Eugene.

    好的。謝謝你,Eugene。

  • - Chairman

    - Chairman

  • Oh, you're welcome.

    不客氣。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,接著提出您的問題。

  • Hey, good morning. from Salomon Smith Barney. I have a question but you just caught me by surprise on Zovirax cream by saying that's already filed.

    嗨,早安。我來自Salomon Smith Barney。我有個問題,不過你剛剛提到Zovirax乳膏已經送件,讓我有點措手不及。

  • - Chairman

    - Chairman

  • Yes. The submission is in. We're just waiting for some feedback from the FDA on clarification of any issues that they might have.

    是的。申請已經遞交。我們正在等待FDA回覆,釐清他們可能提出的任何問題。

  • OK. Excellent. That seems a little bit faster than anticipated that I had previously thought maybe mid year.

    好的。很好。這比我原先預期的快一些;我之前以為可能要到年中。

  • - Chairman

    - Chairman

  • Well, I'm not sure why the mid year, but we had always said in the first half so maybe that was the misunderstanding.

    嗯,我不確定為什麼會是年中,但我們一直都說是在上半年,所以可能是理解上的落差。

  • OK. Excellent. And then my real question was more along the co-promotion royalty licensing income line and the, you know, taking the Celexa co-promotion in Canada and moving it into that line. Are the historicals for 2001 available there, , so we know what we need to change in our model?

    好的。很好。那我真正的問題是關於共同推廣(co-promotion)權利金/授權收入那一塊,以及你們把加拿大的Celexa共同推廣移到那個科目。, 2001年的歷史數據在那裡是否可取得,讓我們知道模型需要怎麼調整?

  • Yeah, you'll be able to track that, basically, if you look at product sales for Q1 2001, as we reported today versus the product sales that we reported back in April of last year. You'll see a difference, I believe, the different is about $3.5 million to $4 million.

    可以,你可以追得出來。基本上,如果你比較我們今天公布的2001年第一季產品銷售額,與去年4月我們當時公布的產品銷售額,你會看到差異;我相信差異大約是350萬到400萬美元。

  • It is pretty steady going forward if I wanted to adjust to '02 through '04?

    如果我要調整2002到2004年,往後會相當穩定嗎?

  • It's not totally linear but at the end of the day, it's somewhere between $15 to $20 million on a total year basis. OK?

    不會完全線性,但總體而言,以全年合計大約在1,500萬到2,000萬美元之間。可以嗎?

  • And that does have an impact on the margins, so historically where you've seen margins, you know, a 76 percent range, 77 percent range, by pulling obviously that out of the product sales, it lowers product sales, it lowers therefore the gross margin, but keep in mind by moving that revenue down to the co-promote line, it of course all falls to the bottom line. So where historically you were including say Celexa co-promote revenues and product sales, you were only taking 75 percent or 76 percent of it. Now as it always has, it's always fallen right to the bottom line. So there will be a slight, from a historical perspective, margins will come down a little bit but not profitability.

    而這確實會影響毛利率,所以過去你看到的毛利率大概在76%、77%區間;把這部分從產品銷售中抽出後,產品銷售會降低,因此毛利率也會降低。但請記住,把這筆收入移到共同推廣那一行後,它當然會全部落到淨利。也就是說,過去你把例如Celexa共同推廣收入納入產品銷售時,你只取其中75%或76%。現在如同一直以來,它會直接落到淨利。因此從歷史角度看,毛利率會稍微下降,但獲利能力不會下降。

  • Excellent. And then on the Manitoba facility or the manufacturing facilities expansions, are those paid for by Biovail or Glaxo?

    很好。那麼關於曼尼托巴廠或製造設施的擴建,這些是由 Biovail 還是 Glaxo 支付?

  • - Chairman

    - Chairman

  • No, those are paid by Biovail. But they're of course factored into the cost, into our transfer pricing, I mean, that was all thought through. Total cap backs on those expansions is approximately $10 million.

    不,這些是由 Biovail 支付。但當然這些已被納入成本、也納入我們的移轉訂價,我是說,這些都已經事先考量過。這些擴建的資本支出總額約為 1,000 萬美元。

  • Great. That's very helpful. Thank you.

    太好了。這非常有幫助。謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,然後提出您的問題。

  • Hi, B&L Investment Firms. , I have a question regarding your sales breakdown regarding Cardizem.

    嗨,B&L Investment Firms。, 我有一個關於 Cardizem 銷售拆分的問題。

  • How much of the Cardizem would be in Canada, because if I use the 40 percent, I get $52 million, which would be much higher than anticipated and I'm just wondering why that is?

    Cardizem 在加拿大的部分有多少?因為如果我用 40%,我算出來是 5,200 萬美元,這會比預期高很多,我只是想知道為什麼會這樣?

  • There is a component in Q1 that relates to Canada. I haven't broken it down for you, but there is a component that does relate to that.

    第一季有一個部分與加拿大有關。我沒有替你拆得那麼細,但確實有一部分是與加拿大相關的。

  • And what kind of size would Canada be?

    那加拿大大概會是什麼規模?

  • I haven't broken down that relationship between US versus Canada. It is, you know, it's down from Q4 levels, but you know, Cardizem as it has done continuously since we bought it, still tracks very nicely for us.

    我沒有把美國與加拿大之間的關係拆開來。它,你知道的,相較第四季水準是下降了,但你知道,Cardizem 自從我們買下來以後一直如此,對我們來說仍然表現得非常好。

  • OK. And when you talk about Canadian being less than 5 percent, you exclude Cardizem and Celexa on that?

    好的。那你提到加拿大占比低於 5% 時,有把 Cardizem 和 Celexa 排除在外嗎?

  • Yes, that is correct. I'm excluding both Cardizem and Celexa, yes.

    是的,沒錯。我把 Cardizem 和 Celexa 都排除在外,是的。

  • And can you just give us some color about going forward regarding SG&A increase, you know, in line with the southward expansion and marketing expenses, how much of an increase can we expect quarter to quarter going forward? What should we be tracking, looking to?

    另外,你能否談談未來 SG&A 增加的情況?你知道,隨著向南擴張與行銷費用,未來每季相較前一季大概會增加多少?我們應該追蹤、關注什麼?

  • Well, we continue to believe that our SG&A will be in line with the previously stated guidance of a 20 percent to 25 percent range on total revenues. And of course within that range we do see SG&A escalating over the course of the year but of course so far revenues.

    我們仍然相信,我們的 SG&A 將符合先前所提供的指引:占總營收的 20% 到 25%。當然,在這個區間內,我們確實看到 SG&A 會在一年當中逐步上升,但當然營收也是如此。

  • OK. And you're waiting for just a couple of additional strengths approved on your generic Naphetapines, any timelines for that?

    好的。你們正在等待你們的學名藥 Naphetapines 再核准幾個額外劑量規格,有沒有時間表?

  • - Chairman

    - Chairman

  • Yeah, I believe both cc 90 mg and XL 90 mg will be in the marketplace later this year, certainly by the end of this year.

    有的,我相信 cc 90 mg 和 XL 90 mg 都會在今年稍晚上市,肯定會在今年年底前。

  • OK. And my last question is, can we expect any further GSK R & D funding for the rest of the year?

    好的。我最後一個問題是:今年剩下的時間,我們還能期待 GSK 進一步提供研發資金嗎?

  • - Chairman

    - Chairman

  • Yes. We do expect that to occur. That is part of the relationship.

    是的。我們確實預期會發生。這是合作關係的一部分。

  • And, same kind of magnitude we've seen in Q1?

    而且規模會跟第一季看到的差不多嗎?

  • - Chairman

    - Chairman

  • I would imagine so, yeah.

    我想應該會,是的。

  • OK. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,然後提出您的問題。

  • Hi. Good morning. I'm from Parodyne Capital. Just two quick accounting questions. I guess since the change in the rule regarding the amortization of goodwill, are you putting the GSK $133 million payment into instead of an expansion, are you kind of just putting it back into intangible assets? And I would like to know what kind of timing should we expect that to be expense or when would that eventually show up in the income statement?

    嗨,早安。我來自 Parodyne Capital。兩個簡短的會計問題。我想,因為攤銷商譽規則的變更,你們是否把 GSK 的 1.33 億美元付款,與其視為擴張,不如說是把它放回無形資產?另外我想了解,這筆費用大概會在什麼時間點認列,或最終何時會出現在損益表上?

  • - Chairman

    - Chairman

  • The product rights associated with Zovirax are capitalized, that $133 million is not treated as goodwill under the accounting rules, it is a product right and therefore it is amortized over the period of time and that period of time is ten years.

    與 Zovirax 相關的產品權利是資本化處理的;那 1.33 億美元依會計準則不被視為商譽,而是產品權利,因此會在一段期間內攤銷,而該期間是十年。

  • OK. And that's also impact on the investment cash outflow in I guess Q1 02, right?

    好的。那這也會影響我想是 2002 年第一季的投資現金流出,對嗎?

  • - Chairman

    - Chairman

  • Yeah, it was part of Q1 '02 yes financing activities, absolutely.

    是的,它是 2002 年第一季的一部分,沒錯,是融資活動,完全正確。

  • And what's the total shares outstanding? I know you reported the weighted average, do you have an approximate number of outstanding fully diluted shares at the end of the quarter?

    那流通在外股數總數是多少?我知道你們報告了加權平均數,季度末大概有多少完全稀釋後的流通在外股數?

  • - Chairman

    - Chairman

  • Well, outstanding is about $152 million and fully diluted was disclosed to just about $166 million.

    嗯,流通在外大約是 1.52 億股,完全稀釋後已揭露約為 1.66 億股。

  • And finally for the Biovail USA, the product included in the Biovail USA, what are those products again?

    最後,關於 Biovail USA,Biovail USA 裡面包含的產品有哪些?可以再說一次嗎?

  • - Chairman

    - Chairman

  • Yeah, those products include the Cedax product line, , and Zovirax and Rondec, excuse me.

    好的,這些產品包括 Cedax 產品線、, 以及 Zovirax 和 Rondec,不好意思。

  • Thank you very much.

    非常感謝。

  • - Chairman

    - Chairman

  • Pleasure.

    不客氣。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,然後提出您的問題。

  • Sure, it's Research Capital and just had two questions. One is if you could just give a rough breakdown of the co-promotion on royalty and licensing line and then also just notice that for the fourth quarter your revenue went down by about $5.1 million, just wanted to know what that was attributed to?

    好的,我是 Research Capital,有兩個問題。第一個是你能否大致拆分一下共同推廣在權利金與授權那一行的構成;另外也注意到第四季你們營收下降了約 510 萬美元,想了解那是因為什麼原因?

  • - Chairman

    - Chairman

  • Yeah, certainly. On the co-promotion, we did earn the full amount under the relationship with Glaxo, so there is roughly $10 million, over $10 million from Glaxo as it relates to that. The Celexa promotions were, the revenue from that were in line with last years so in the $3 to $5 million range and the balance were royalties.

    好的,當然可以。關於共同推廣,我們在與 Glaxo 的合作關係下確實賺取了全額,所以與此相關、來自 Glaxo 的大約是 1,000 萬美元以上。Celexa 推廣的收入與去年一致,大約在 300 萬到 500 萬美元區間,其餘則是權利金。

  • Operator

    Operator

  • , please go ahead with your follow-up question.

    , 請繼續提出您的追問。

  • Just as it relates to Cardizem XL at the FDA, given that the FDA seems to be reluctant to approve a lot of things these days, can you give us some sort of comfort on your dialogue with the agency and is there any reason that we would be, should be concerned about approval timelines? And also, was it filed as a 505B or was it just a new straight NDA?

    就 Cardizem XL 在 FDA 的進度而言,鑑於 FDA 近來似乎不太願意核准很多東西,你能否就你們與主管機關的溝通給我們一些信心?是否有任何理由讓我們需要擔心核准時程?另外,它是以 505B 申請,還是直接以新的 NDA 申請?

  • - President

    - President

  • It was filed as a new straight NDA and no, there is nothing that we are aware of that should be concerning us or any investors. We do expect an approval later this year. There has been no issues. We know the study results, we're very familiar with the drug having a lot of experience with Diltiazem so no, there is nothing, there is no real expectation of anything negative.

    它是以全新的、直接的 NDA 申請;而且不,我們沒有注意到任何應該讓我們或任何投資人擔心的事情。我們確實預期今年稍晚會獲得核准。沒有任何問題。我們知道研究結果,我們對這個藥非常熟悉,因為我們在 Diltiazem 上有很多經驗,所以不,沒有任何事情——沒有任何真正預期會有負面結果。

  • You said that Wellbutrin XL you might expect that that be slated for a ten month review, have you had said anything similar about Cardizem XL?

    你說 Wellbutrin XL 可能會是 10 個月審查期,那 Cardizem XL 你們有說過類似的情況嗎?

  • - President

    - President

  • No. We know that the date is sometime mid this summer, but no we don't have that specific, that kind of specificity.

    沒有。我們知道日期大概在今年夏天年中左右,但我們沒有那麼具體、那種程度的明確性。

  • OK. Great. Thanks.

    好的。太好了。謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,然後提出您的問題。

  • . I just had a quick question on Keftab, can we get an update there? And I was wondering if there was any sort of settlement in the quarter and also curious to know on the Tramadol, those trials your starting, is that with the same formulation that you've used in the earlier trials, or is that a new formulation that you might have gotten from ?

    . 我有一個關於 Keftab 的簡短問題,可以給我們一個最新進度嗎?另外我想知道本季是否有任何和解;也想請教 Tramadol,你們正在開始的那些試驗,是使用你們在先前試驗中用過的相同配方,還是你們可能從取得的新配方?

  • - Chairman

    - Chairman

  • No. It's the same formulation, you know, the same formulation as the previous studies were done on. And I'm sorry , what was your first question?

    不,是相同配方,你知道的,和先前研究所用的是同一個配方。不好意思, 你的第一個問題是什麼?

  • Just with regard to Keftab, has there been any settlement there with Lilly?

    就是關於 Keftab,和 Lilly 那邊是否有任何和解?

  • - Chairman

    - Chairman

  • No. There is no settlement and there were no settlement dollars in the first quarter. So that's just going through as a straightforward litigation.

    沒有。沒有任何和解,而且第一季也沒有任何和解金額。所以那就是按一般訴訟程序進行。

  • OK. Thank you.

    好的。謝謝。

  • - Chairman

    - Chairman

  • You're welcome.

    不客氣。

  • Operator

    Operator

  • , please state your company name followed by your question.

    , 請先說明您的公司名稱,然後提出您的問題。

  • Hi. , first of all I was a little confused, you said Cardizem CD was, I think we were seeing about $52 million in the quarter, and you said that was down from fourth quarter levels.

    嗨。, 首先我有點困惑,你說 Cardizem CD 我想我們看到本季大約是 5,200 萬美元,而你說那是低於第四季水準。

  • I thought that that was up from fourth quarter levels, so if you could just clarify that. Second of all, on the sales reps, you said that 150 are just coming out of training, so that adds to the 300, so should I assume around 450? And if that's the case, what are they going to be marketing until Cardizem XL, just kind of give us the sense of, you know, the one-two there.

    我以為那是高於第四季水準,所以如果你能澄清一下。第二,關於業務代表,你說有 150 位剛結束訓練,所以加上原本的 300 位,我是否應該假設大約 450 位?如果是這樣,在 Cardizem XL 上市之前,他們要行銷什麼?請給我們一些脈絡,你知道的,那個前後銜接。

  • And on Tramadol, let me just make sure I understand something, we had the two trials that were completed and we saw data that came across on a press release over the past year and my understanding is that there were open label studies that were going to be ongoing until the end of the year in order to get the, you know, the requisite number of patients for ICH guidelines and a filing was supposed to be late this year, early next year, so I just want to make sure that, I mean, have you guys made it a new decision on different types of trials or did I just misunderstand it the first time? Thanks.

    另外關於 Tramadol,讓我確認我是否理解正確:我們完成了兩個試驗,過去一年我們也在新聞稿中看到相關數據;我的理解是,為了符合 ICH 指引所需的病患數,你們會持續進行開放標籤研究直到年底,並且原本預計今年稍晚或明年初申報,所以我想確認一下——你們是否做了新的決定、改做不同類型的試驗,還是我一開始就誤解了?謝謝。

  • - Chairman

    - Chairman

  • OK, , let me answer the first question on Tramadol because it's pretty straightforward and I think Bill can talk a little bit more about what the sales force is going to do and, you know, between now and the XL launch. The Tramadol we have added an additional trial and expanded the initial one by the number of patients. We needed more numbers to meet those ICH guidelines. We've also included in the trials an additional indication that we're going to be pursuing and that's basically it. I mean, the additional time that it's going to take to add this additional trial and expand the first one is . So when we're looking at pushing something out, we're looking at somewhere towards the end of the first quarter into the second quarter of next year. And that assumes that patient was fine which up until now has been going very well. Bill, do you want to just talk about the ...

    好的,,我先回答第一個關於 Tramadol 的問題,因為這相當直接,而且我想 Bill 可以再多談一點銷售團隊將要做什麼,以及你知道的,在現在到 XL 上市之間。關於我們的 Tramadol,我們新增了一項額外的試驗,並且透過增加受試者人數擴大了原先的試驗。我們需要更多樣本數以符合那些 ICH 指南。我們也在試驗中納入了一個我們將要推進的額外適應症,基本上就是這樣。我的意思是,為了新增這項額外試驗並擴大第一項試驗所需的額外時間是。因此,當我們評估把某些事項往後推時,我們預期大約會落在明年第一季末到第二季之間。這也假設受試者招募進展順利,而到目前為止一直都進行得很好。Bill,你要不要談一下……

  • - President

    - President

  • Yeah, no problem, Eugene. , with respect to the sales organization, the ones that are just coming out of their training programs are deployed into their territories, they'll be spending a number of weeks getting around those territories, clarifying what it is they are doing and of course we're looking towards the latter part of this quarter to start the promotion of and once we get, as had mentioned earlier, once we get fully up to speed on the samples with Zovirax, then they'll be starting that as well. Don't forget as well that we are still finishing off a little bit of Cedax so they're keeping busy with that respect, with that product as well.

    好的,沒問題,Eugene。,就銷售組織而言,剛從訓練計畫結業的成員已部署到各自的區域,他們會花幾週時間熟悉那些區域,釐清他們要做的工作;當然,我們也預計在本季後段開始推廣,而且一旦我們如先前提到的,一旦 Zovirax 的樣品供應完全到位,他們也會開始推動。也別忘了,我們仍在收尾一點 Cedax,因此他們在那方面也很忙,該產品也讓他們保持忙碌。

  • So we are around 450?

    所以我們大約是 450?

  • - President

    - President

  • Oh, I'm sorry. Yes, the number is, in the 450 range is a good number, yes.

    喔,抱歉。是的,數字在 450 左右是個不錯的數字,是的。

  • And one other question, . Earlier you were talking about Ash and I was just a little confused on exactly which day things were happening. I'm familiar that the poster session is Saturday morning. There was something at you mentioned, I wasn't sure which day you were referring to. Maybe you could just kind of tell us exactly which days we need to be there in order to participate in Biovail events?

    還有另一個問題,。先前你在談 Ash,我對於事情究竟是哪一天發生有點困惑。我知道海報展示是週六早上。你提到在有某個活動,我不確定你指的是哪一天。也許你可以告訴我們,若要參與 Biovail 的活動,我們到底需要哪幾天到場?

  • - Vice President of Finance

    - Vice President of Finance

  • Sure. Pleased to do so. Also on the Friday, May 17th, there are a number of activities, the abstract is presented Friday morning, symposiums ongoing on Friday and we are planning small analyst event on the Friday, we're targeting right now at 1:30, we hope to finalize those plans so that we can talk to you more about that in the coming days. But certainly we are planning on doing something Friday afternoon. One of the lead investigators available to not only present the data but be available for questions and answers and provide any additional information that people might be interested in.

    當然,很樂意。也在週五(5 月 17 日)會有一些活動:摘要在週五上午發表,週五也有持續進行的研討會;我們計畫在週五安排一個小型分析師活動,目前目標時間是 1:30,我們希望能在接下來幾天敲定計畫,以便再跟各位多談。不過可以確定的是,我們計畫在週五下午做一些安排。屆時會有一位主要研究者出席,不僅會呈現數據,也會接受問答,並提供大家可能感興趣的任何補充資訊。

  • Thanks.

    謝謝。

  • Operator

    Operator

  • , please go ahead with your follow-up question.

    ,請繼續提出您的追問。

  • Great. Thanks very much. I had one quick question to clarify the number that you reported for the co-promote. I think you mentioned in the quarter it was roughly $10 million, I seem to recall that in the fourth quarter, you booked revenue but pushed it into the first quarter so I was curious if the $10 million includes some of that revenue or if there was some incremental amount for the Wellbutrin SR co-promote?

    很好。非常感謝。我有一個簡短問題,想釐清你們所報告的共同推廣(co-promote)數字。我記得你提到本季大約是 1,000 萬美元;我似乎記得在第四季你們認列了收入但把它延後到第一季,所以我想知道這 1,000 萬美元是否包含其中一部分收入,或是 Wellbutrin SR 共同推廣是否還有額外的增量金額?

  • - Vice President of Finance

    - Vice President of Finance

  • The co-promote revenues in Q1 '02 relates specifically to co-promote revenues and activities that occurred in Q1. Any of the revenues or amounts from Q4, you know, that came into Q1 basically related to the developmental work and the developmental activities that took place in Q1 '02.

    2002 年第一季的共同推廣收入,係專指第一季所發生的共同推廣收入與活動。至於任何來自第四季、你知道的、進到第一季的收入或金額,基本上是與 2002 年第一季所進行的開發工作與開發活動相關。

  • So the revenue was booked in the fourth quarter?

    所以收入是在第四季認列的?

  • - Vice President of Finance

    - Vice President of Finance

  • No, there were no revenues booked in the fourth quarter related to the arrangements with Glaxo, nothing. No, there was nothing in the P&L.

    不,與 Glaxo 的安排相關的收入在第四季沒有認列,完全沒有。不,損益表裡沒有任何東西。

  • OK. So there was additional income above the $10 million for other developmental work related to the manufacturing? Is that ...

    好的。所以除了那 1,000 萬美元之外,還有與製造相關的其他開發工作帶來的額外收入?是這樣嗎……

  • - Vice President of Finance

    - Vice President of Finance

  • That is correct. In the co-promote royalty and licensing line, there was $10 million as it relates to the promotional activities around Wellbutrin SR. In addition, in the R&D revenue line, there was some revenue associated with the developmental activities on Wellbutrin once daily in the R&D revenue line.

    沒錯。在共同推廣權利金與授權(co-promote royalty and licensing)那一行,與 Wellbutrin SR 的推廣活動相關的是 1,000 萬美元。此外,在研發收入(R&D revenue)那一行,還有一些與 Wellbutrin 每日一次(once daily)之開發活動相關的收入,列在研發收入那一行。

  • Great. Thanks, .

    很好。謝謝,。

  • - Vice President of Finance

    - Vice President of Finance

  • Sure.

    當然。

  • Operator

    Operator

  • Ladies and gentlemen, if there are any additional or follow-up questions at this time, please press the one on your touch-tone phone. , please go ahead with your follow-up question.

    各位女士先生,如果此時還有任何其他或追問問題,請按下您按鍵式電話上的 1。,請繼續提出您的追問。

  • Can you give us some ideas on price increases that have occurred over the last six months for Zovirax and the Cardizem?

    你能否提供一些想法,關於過去六個月 Zovirax 和 Cardizem 的漲價情況?

  • - Chairman

    - Chairman

  • Do you want me to take that ?

    你要我回答這個嗎?

  • - Vice President of Finance

    - Vice President of Finance

  • Yeah, sure.

    好,當然。

  • - Chairman

    - Chairman

  • , in terms of Zovirax, there was a price increase in January of this year in the double-digit range and that was for Zovirax. And on the Cardizem, there was no price increase this year in the last six months.

    ,就 Zovirax 而言,今年 1 月有一次漲價,幅度為兩位數百分比,這是針對 Zovirax。至於 Cardizem,在過去六個月、今年並沒有漲價。

  • This would include Q4 last year, right?

    這也包含去年第四季,對吧?

  • - Chairman

    - Chairman

  • That's correct.

    沒錯。

  • OK. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • , please state your company name followed by your question.

    ,請先說明您的公司名稱,接著提出您的問題。

  • Yes, , and I'm sorry, I had a phone problem earlier. , a follow-up on the Zovirax price increase question, and we launch later in this quarter, are you anticipating additional price increases as you re-launch and reposition the product?

    是的,,很抱歉,我剛才電話出了點問題。,針對 Zovirax 漲價問題的追問:我們在本季稍晚重新上市,你們是否預期在重新上市並重新定位產品時會有額外的漲價?

  • - President

    - President

  • At this point, we're only considering that, . No firm, as I stated, we just put one in in the first quarter, so there is no firm plan to put one in the second quarter on anything like that.

    目前我們只是考慮中,。如我所說,我們在第一季才剛調過一次,所以並沒有確定計畫要在第二季再做任何類似的調價。

  • OK. Great. Thank you.

    好的。很好。謝謝。

  • Operator

    Operator

  • At this time I am showing no further questions. Please continue with any closing comments.

    目前我這邊顯示沒有其他問題。請繼續進行任何結語。

  • - Chairman

    - Chairman

  • Well, thank you, everyone for joining our call today and especially to the employees of Biovail who contributed to this record quarter which -- we know that they listen in to these calls and I'd like to thank them on behalf of senior management and the directors. Again, thank you very much and look forward to having everyone on our second quarter conference call in about three months time. Thank you very much.

    那麼,感謝各位今天參與我們的電話會議,特別要感謝 Biovail 的員工,他們為這個創紀錄的季度做出了貢獻——我們知道他們也會收聽這些電話會議——我謹代表高階管理團隊與董事向他們致謝。再次非常感謝,也期待大約三個月後在我們第二季的電話會議上與各位再會。非常感謝。

  • Operator

    Operator

  • Ladies and gentlemen, that does conclude today's Biovail conference call. You may all disconnect and thank you for participating.

    各位女士先生,今天的 Biovail 電話會議到此結束。各位可以掛線,感謝您的參與。

  • END

    結束